Gilead goes strong
By on Mar 12, 2009 in Finances
Another day, another drugmaker merger. On Thursday Gilead Sciences joined the industry’s acquisition binge by agreeing to buy CV Therapeutics for $1.4 billion in cash.
Original post by Technology news - Business 2.0 Magazine
You must be logged in to post a comment.